Details
Stereochemistry | EPIMERIC |
Molecular Formula | C19H21N3S.C4H6O6 |
Molecular Weight | 473.542 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H]([C@@H](O)C(O)=O)C(O)=O.CC(CN(C)C)CN1C2=CC=CC=C2SC3=CC=C(C=C13)C#N
InChI
InChIKey=OVSVMCBAXAWPTR-LREBCSMRSA-N
InChI=1S/C19H21N3S.C4H6O6/c1-14(12-21(2)3)13-22-16-6-4-5-7-18(16)23-19-9-8-15(11-20)10-17(19)22;5-1(3(7)8)2(6)4(9)10/h4-10,14H,12-13H2,1-3H3;1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1
Molecular Formula | C19H21N3S |
Molecular Weight | 323.455 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | C4H6O6 |
Molecular Weight | 150.0868 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class used primarily in the treatment of schizophrenia and psychosis-associated anxiety. Cyamemazine actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects and lack of extrapyramidal side effects. Cyamemazine is used for the treatment of chronic psychotic states, anxiety, major depression.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P21728 Gene ID: 1812.0 Gene Symbol: DRD1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12527336 |
3.8 nM [Ki] | ||
Target ID: CHEMBL234 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12527336 |
2.5 nM [Ki] | ||
Target ID: P28223 Gene ID: 3356.0 Gene Symbol: HTR2A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12527336 |
1.5 nM [Ki] | ||
Target ID: P28335 Gene ID: 3358.0 Gene Symbol: HTR2C Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12527336 |
12.0 nM [Ki] | ||
Target ID: CHEMBL2095203 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12527336 |
2.3 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TERCIAN Approved UseChronic psychotic states (schizophrenia, chronic non-schizophrenic delusions: paranoid delusions, chronic hallucinatory psychoses). |
|||
Primary | TERCIAN Approved UseShort-term symptomatic treatment of adult anxiety in case of failure of usual therapies. |
|||
Primary | TERCIAN Approved UseIn combination with an antidepressant, short-term treatment of some severe forms of major depressive episode. |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
5-HT2A receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle. | 2002 Nov 15 |
|
A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression. | 2002 Oct |
|
[Catatonia de novo, report on a case: immediate vital prognosis and psychiatric prognosis in longer term]. | 2003 Jan-Feb |
|
Acute fatal poisoning with cyamemazine. | 2003 Oct 14 |
|
Interspecies variability and drug interactions of loxapine metabolism in liver microsomes. | 2003 Oct-Dec |
|
Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome. | 2004 Fall |
|
Primary photochemical processes of the phototoxic neuroleptic cyamemazine: a study by laser flash photolysis and steady-state irradiation. | 2004 Nov-Dec |
|
False-positive results in the detection of methadone in urines of patients treated with psychotropic substances. | 2005 Nov |
|
Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine. | 2007 Dec |
|
Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study. | 2007 Jun |
|
[Acute Datura stramonium poisoning in an emergency department]. | 2007 Oct |
|
Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes. | 2008 Jan 14 |
|
[Prescribing patterns of antipsychotics in 13 French psychiatric hospitals]. | 2009 Apr |
|
Antipsychotics-induced ischaemic colitis and gastrointestinal necrosis: a review of the French pharmacovigilance database. | 2009 Oct |
|
Buprenorphine-related deaths: unusual forensic situations. | 2010 Nov |
Patents
Sample Use Guides
Oral: 25-600 mg daily in 2 or 3 divided doses with larger doses taken at night. Intramuscular: 25-200 mg daily.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12527336
Binding to receptors was carried out using radioligand binding assay. Suspension of cells, expressing the receptor was incubated with cyamemazine and a reference radioligand. At the end of incubation period, membranes or cells were rapidly filtered under vacuum conditions through glass fiber filters. Bound radioactivity was measured with a scintillation counter. Each competition concentration-response curve was determined in duplicated using cyamemazine concentration spanning from 0.03 nM to 30-100 uM
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 04:40:33 UTC 2023
by
admin
on
Sat Dec 16 04:40:33 UTC 2023
|
Record UNII |
C4ZT3BE459
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
24892868
Created by
admin on Sat Dec 16 04:40:33 UTC 2023 , Edited by admin on Sat Dec 16 04:40:33 UTC 2023
|
PRIMARY | |||
|
93841-82-8
Created by
admin on Sat Dec 16 04:40:33 UTC 2023 , Edited by admin on Sat Dec 16 04:40:33 UTC 2023
|
PRIMARY | |||
|
236251
Created by
admin on Sat Dec 16 04:40:33 UTC 2023 , Edited by admin on Sat Dec 16 04:40:33 UTC 2023
|
PRIMARY | RxNorm | ||
|
100000088201
Created by
admin on Sat Dec 16 04:40:33 UTC 2023 , Edited by admin on Sat Dec 16 04:40:33 UTC 2023
|
PRIMARY | |||
|
C4ZT3BE459
Created by
admin on Sat Dec 16 04:40:33 UTC 2023 , Edited by admin on Sat Dec 16 04:40:33 UTC 2023
|
PRIMARY | |||
|
SUB01510MIG
Created by
admin on Sat Dec 16 04:40:33 UTC 2023 , Edited by admin on Sat Dec 16 04:40:33 UTC 2023
|
PRIMARY | |||
|
DTXSID70917530
Created by
admin on Sat Dec 16 04:40:33 UTC 2023 , Edited by admin on Sat Dec 16 04:40:33 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |